[18F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab
Alberto Signore(CTO Andrea Alesini), Agostino Tafuri(Azienda Ospedaliera Sant'Andrea), Maria Luisa Martini(CTO Andrea Alesini), Fabio Trapasso(CTO Andrea Alesini), Antonio Aceti(Sapienza University of Rome), Chiara Lauri(Azienda Ospedaliera Sant'Andrea), Luciano De Biase(Azienda Ospedaliera Sant'Andrea), Maria Paola Bianchi(Azienda Ospedaliera Sant'Andrea), Andrea Lenza(CTO Andrea Alesini), Gabriele Franchi, Sabrina Pelliccia(Azienda Ospedaliera Sant'Andrea), Simone Tetti(Sapienza University of Rome)
Cited by 5
Related Papers
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Guidelines for the labelling of leucocytes with 99mTc-HMPAO
|European Journal of Nuclear Medicine and Molecular Imaging|2010|239
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
|Blood|2019|215
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation
|Clinical and Translational Imaging|2021|171